JP2018524367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524367A5 JP2018524367A5 JP2018501285A JP2018501285A JP2018524367A5 JP 2018524367 A5 JP2018524367 A5 JP 2018524367A5 JP 2018501285 A JP2018501285 A JP 2018501285A JP 2018501285 A JP2018501285 A JP 2018501285A JP 2018524367 A5 JP2018524367 A5 JP 2018524367A5
- Authority
- JP
- Japan
- Prior art keywords
- cyano
- pyrrolidine
- carbonitrile
- carbonyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- -1 methoxyethoxy Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 230000007812 deficiency Effects 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000005529 alkyleneoxy group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 208000008955 Mucolipidoses Diseases 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 206010058892 Carnitine deficiency Diseases 0.000 claims 2
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 2
- 208000006443 lactic acidosis Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 230000004065 mitochondrial dysfunction Effects 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 102000045222 parkin Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- COKNKHWUKNJCMB-ZDUSSCGKSA-N (2S)-1-cyano-N-(5-cyano-4-phenyl-1,3-thiazol-2-yl)-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC(=C(N=1)C1=CC=CC=C1)C#N COKNKHWUKNJCMB-ZDUSSCGKSA-N 0.000 claims 1
- KCPHOFOOLGXKGK-HNNXBMFYSA-N (2S)-1-cyano-N-[3-(3-methoxyphenyl)-1,2-oxazol-5-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C1=CC(=NO1)C1=CC(=CC=C1)OC KCPHOFOOLGXKGK-HNNXBMFYSA-N 0.000 claims 1
- DCBBFYWGMDFIRP-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(2-cyanopyridin-4-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=CC(=NC=C1)C#N DCBBFYWGMDFIRP-AWEZNQCLSA-N 0.000 claims 1
- IJXKVEAWLXTUTE-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(2-methoxyphenyl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=C(C=CC=C1)OC IJXKVEAWLXTUTE-AWEZNQCLSA-N 0.000 claims 1
- LJALYPZMAKFPSM-HNNXBMFYSA-N (2S)-1-cyano-N-[4-(3-cyanophenyl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=CC(=CC=C1)C#N LJALYPZMAKFPSM-HNNXBMFYSA-N 0.000 claims 1
- RPKFCLFVAACYOG-ZDUSSCGKSA-N (2S)-1-cyano-N-[4-(3-cyanophenyl)-5-fluoro-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC(=C(N=1)C1=CC(=CC=C1)C#N)F RPKFCLFVAACYOG-ZDUSSCGKSA-N 0.000 claims 1
- VJDMCZGYBLAWAZ-INIZCTEOSA-N (2S)-1-cyano-N-[4-(3-ethylphenyl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=CC(=CC=C1)CC VJDMCZGYBLAWAZ-INIZCTEOSA-N 0.000 claims 1
- HAGHQCDRXRUHJX-HNNXBMFYSA-N (2S)-1-cyano-N-[4-(3-methoxyphenyl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=CC(=CC=C1)OC HAGHQCDRXRUHJX-HNNXBMFYSA-N 0.000 claims 1
- YVXVYNHRYPBFFU-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(5-cyanopyridin-3-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C=1C=NC=C(C=1)C#N YVXVYNHRYPBFFU-AWEZNQCLSA-N 0.000 claims 1
- KFVZUBKAWMNHOI-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(6-cyano-3-ethoxypyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1OCC)C#N KFVZUBKAWMNHOI-AWEZNQCLSA-N 0.000 claims 1
- AAKVUGNGGLMSKC-ZDUSSCGKSA-N (2S)-1-cyano-N-[4-(6-cyano-3-methoxypyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1OC)C#N AAKVUGNGGLMSKC-ZDUSSCGKSA-N 0.000 claims 1
- ZUBBSKORVRCGAW-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(6-cyano-3-methylpyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1C)C#N ZUBBSKORVRCGAW-AWEZNQCLSA-N 0.000 claims 1
- SDXFIPRXASXHKJ-HNNXBMFYSA-N (2S)-1-cyano-N-[4-(6-cyano-5-ethoxypyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=C(C=C1)OCC)C#N SDXFIPRXASXHKJ-HNNXBMFYSA-N 0.000 claims 1
- APFKLZAHDDDAOH-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(6-cyano-5-methoxypyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=C(C=C1)OC)C#N APFKLZAHDDDAOH-AWEZNQCLSA-N 0.000 claims 1
- AFWVFDKSXQAVKQ-HNNXBMFYSA-N (2S)-1-cyano-N-[4-(6-cyano-5-methylpyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=C(C=C1)C)C#N AFWVFDKSXQAVKQ-HNNXBMFYSA-N 0.000 claims 1
- RWUYLRLELHSDQH-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(6-cyanopyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1)C#N RWUYLRLELHSDQH-AWEZNQCLSA-N 0.000 claims 1
- WDNHBRPZDSJTGI-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(6-cyanopyridin-2-yl)-5-ethyl-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC(=C(N=1)C1=NC(=CC=C1)C#N)CC WDNHBRPZDSJTGI-AWEZNQCLSA-N 0.000 claims 1
- HHRMQBUASZODPH-AWEZNQCLSA-N (2S)-1-cyano-N-[4-(6-cyanopyridin-2-yl)-5-methyl-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC(=C(N=1)C1=NC(=CC=C1)C#N)C HHRMQBUASZODPH-AWEZNQCLSA-N 0.000 claims 1
- JELYJKAQAGOBRO-INIZCTEOSA-N (2S)-1-cyano-N-[4-(6-cyclopropylpyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1)C1CC1 JELYJKAQAGOBRO-INIZCTEOSA-N 0.000 claims 1
- FJGGYYJGDVVUII-ZDUSSCGKSA-N (2S)-1-cyano-N-[4-(6-methoxypyridin-2-yl)-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1)OC FJGGYYJGDVVUII-ZDUSSCGKSA-N 0.000 claims 1
- ITEZYZUQTSNQSW-INIZCTEOSA-N (2S)-1-cyano-N-[4-[3-(methoxymethyl)phenyl]-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=CC(=CC=C1)COC ITEZYZUQTSNQSW-INIZCTEOSA-N 0.000 claims 1
- BBZPOMQJPPJJMO-HNNXBMFYSA-N (2S)-1-cyano-N-[4-[6-cyano-3-(2-methoxyethoxy)pyridin-2-yl]-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1OCCOC)C#N BBZPOMQJPPJJMO-HNNXBMFYSA-N 0.000 claims 1
- FFNWQIMPGVAHBV-INIZCTEOSA-N (2S)-1-cyano-N-[4-[6-cyano-5-(dimethylamino)pyridin-2-yl]-1,3-thiazol-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=C(C=C1)N(C)C)C#N FFNWQIMPGVAHBV-INIZCTEOSA-N 0.000 claims 1
- JAIBYYLRJLKSSA-HNNXBMFYSA-N (2S)-1-cyano-N-ethyl-N-(4-phenyl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=CC=CC=C1)CC JAIBYYLRJLKSSA-HNNXBMFYSA-N 0.000 claims 1
- NWIHLTTYGVLQQC-AWEZNQCLSA-N (2S)-1-cyano-N-methyl-N-(1-phenylpyrazol-3-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C1=NN(C=C1)C1=CC=CC=C1)C NWIHLTTYGVLQQC-AWEZNQCLSA-N 0.000 claims 1
- LRPSPLJSJDKUIB-AWEZNQCLSA-N (2S)-1-cyano-N-methyl-N-(3-phenyl-1,2-oxazol-5-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C1=CC(=NO1)C1=CC=CC=C1)C LRPSPLJSJDKUIB-AWEZNQCLSA-N 0.000 claims 1
- XYJWIHFCSQUHLU-AWEZNQCLSA-N (2S)-1-cyano-N-methyl-N-(4-phenyl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=CC=CC=C1)C XYJWIHFCSQUHLU-AWEZNQCLSA-N 0.000 claims 1
- QNESVFTZDYIHNM-NSHDSACASA-N (2S)-1-cyano-N-methyl-N-(4-propan-2-yl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C(C)C QNESVFTZDYIHNM-NSHDSACASA-N 0.000 claims 1
- FAJFRTTWIMGORN-ZDUSSCGKSA-N (2S)-1-cyano-N-methyl-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=NC=CC=C1)C FAJFRTTWIMGORN-ZDUSSCGKSA-N 0.000 claims 1
- UVROMVXOLVZJBN-ZDUSSCGKSA-N (2S)-1-cyano-N-methyl-N-(4-pyridin-3-yl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C=1C=NC=CC=1)C UVROMVXOLVZJBN-ZDUSSCGKSA-N 0.000 claims 1
- NJZNESGNKPSFFK-ZDUSSCGKSA-N (2S)-1-cyano-N-methyl-N-(4-pyridin-4-yl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=CC=NC=C1)C NJZNESGNKPSFFK-ZDUSSCGKSA-N 0.000 claims 1
- KNCJNJOLZXCRRY-ZDUSSCGKSA-N (2S)-1-cyano-N-methyl-N-(5-phenyl-1,2-oxazol-3-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C1=NOC(=C1)C1=CC=CC=C1)C KNCJNJOLZXCRRY-ZDUSSCGKSA-N 0.000 claims 1
- XIDYNFKSCDNYHH-ZDUSSCGKSA-N (2S)-1-cyano-N-methyl-N-(5-phenyl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC(=CN=1)C1=CC=CC=C1)C XIDYNFKSCDNYHH-ZDUSSCGKSA-N 0.000 claims 1
- XQZCEIALIBSWOY-HNNXBMFYSA-N (2S)-1-cyano-N-methyl-N-[4-(6-propan-2-yloxypyridin-2-yl)-1,3-thiazol-2-yl]pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C)C=1SC=C(N=1)C1=NC(=CC=C1)OC(C)C XQZCEIALIBSWOY-HNNXBMFYSA-N 0.000 claims 1
- OZUQOMQSCJENAA-KFJBMODSSA-N (2S)-1-cyano-N-methyl-N-[4-(oxolan-3-yl)-1,3-thiazol-2-yl]pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1COCC1)C OZUQOMQSCJENAA-KFJBMODSSA-N 0.000 claims 1
- JQYNODAUGQIMPL-AWEZNQCLSA-N (2S)-1-cyano-N-methyl-N-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=CC(=CC=C1)C(F)(F)F)C JQYNODAUGQIMPL-AWEZNQCLSA-N 0.000 claims 1
- TXCMDMSYSGEVDO-INIZCTEOSA-N (2S)-1-cyano-N-methyl-N-[4-[3-[methyl(methylsulfonyl)amino]phenyl]-1,3-thiazol-2-yl]pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=CC(=CC=C1)N(S(=O)(=O)C)C)C TXCMDMSYSGEVDO-INIZCTEOSA-N 0.000 claims 1
- XCEQUYZBRPULKA-HNNXBMFYSA-N (2S)-2-(1-phenyl-5,6-dihydropyrrolo[3,2-c]pyrazole-4-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)N1N=CC2=C1CCN2C(=O)[C@H]1N(CCC1)C#N XCEQUYZBRPULKA-HNNXBMFYSA-N 0.000 claims 1
- RPNXKHUIZNCHOE-AWEZNQCLSA-N (2S)-2-(4-ethoxy-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C(C)OC1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N RPNXKHUIZNCHOE-AWEZNQCLSA-N 0.000 claims 1
- GHESLAQUATUPKG-IBGZPJMESA-N (2S)-2-(4-phenyl-1,3-dihydroisoindole-2-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=C2CN(CC2=CC=C1)C(=O)[C@H]1N(CCC1)C#N GHESLAQUATUPKG-IBGZPJMESA-N 0.000 claims 1
- GDWRBPHQNJJHCB-IBGZPJMESA-N (2S)-2-(4-phenyl-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N GDWRBPHQNJJHCB-IBGZPJMESA-N 0.000 claims 1
- UEOUYNRYGPLQPF-WMCAAGNKSA-N (2S)-2-(4-pyrazolidin-3-yl-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C1C[C@H](N(C1)C#N)C(=O)N2CCC3=C(C=CC=C32)C4CCNN4 UEOUYNRYGPLQPF-WMCAAGNKSA-N 0.000 claims 1
- HIUWPHSAUQMWQZ-SFHVURJKSA-N (2S)-2-(4-pyridin-2-yl-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound N1=C(C=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N HIUWPHSAUQMWQZ-SFHVURJKSA-N 0.000 claims 1
- WGHVSQRRRUPDBP-SFHVURJKSA-N (2S)-2-(4-pyridin-4-yl-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound N1=CC=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N WGHVSQRRRUPDBP-SFHVURJKSA-N 0.000 claims 1
- HBUQOCHFSXXTAY-FQEVSTJZSA-N (2S)-2-(5-phenyl-3,4-dihydro-2H-quinoline-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=C2CCCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N HBUQOCHFSXXTAY-FQEVSTJZSA-N 0.000 claims 1
- BIFZPYLOFPBBCD-WMCAAGNKSA-N (2S)-2-(5-pyrazolidin-3-yl-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C1C[C@H](N(C1)C#N)C(=O)N2CCC3=C2C=CC(=C3)C4CCNN4 BIFZPYLOFPBBCD-WMCAAGNKSA-N 0.000 claims 1
- BNKOCYHYDZKWKP-SFHVURJKSA-N (2S)-2-(6-phenyl-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=CC=C2CCN(C2=C1)C(=O)[C@H]1N(CCC1)C#N BNKOCYHYDZKWKP-SFHVURJKSA-N 0.000 claims 1
- XOZAOVYOVHMOBC-SFHVURJKSA-N (2S)-2-(8-phenyl-2,3-dihydro-1,4-benzoxazine-4-carbonyl)pyrrolidine-1-carbonitrile Chemical compound O=C([C@@H]1CCCN1C#N)N1CCOC2=C1C=CC=C2C1=CC=CC=C1 XOZAOVYOVHMOBC-SFHVURJKSA-N 0.000 claims 1
- AZVYCCRALWFRRD-INIZCTEOSA-N (2S)-2-[4-(1H-pyrazol-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound N1N=CC(=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N AZVYCCRALWFRRD-INIZCTEOSA-N 0.000 claims 1
- PJYJFXAKGZEDNG-IBGZPJMESA-N (2S)-2-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound N1C=C(C=2C1=NC=CC=2)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N PJYJFXAKGZEDNG-IBGZPJMESA-N 0.000 claims 1
- CRINRUDDKSBHIM-IBGZPJMESA-N (2S)-2-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound N1C=CC=2C1=NC=CC=2C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N CRINRUDDKSBHIM-IBGZPJMESA-N 0.000 claims 1
- ITVHSCOFHWBGHL-KRWDZBQOSA-N (2S)-2-[4-(2H-pyrazolo[3,4-b]pyridin-3-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound N1N=C(C=2C1=NC=CC=2)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N ITVHSCOFHWBGHL-KRWDZBQOSA-N 0.000 claims 1
- MRVYZKBROYHVDF-KRWDZBQOSA-N (2S)-2-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CC1=NOC(=C1C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N)C MRVYZKBROYHVDF-KRWDZBQOSA-N 0.000 claims 1
- PCXSBVQMMUHDPY-RXFZURLPSA-N (2S)-2-[4-(3,5-dimethylpyrazolidin-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CC1C(C(NN1)C)C2=C3CCN(C3=CC=C2)C(=O)[C@@H]4CCCN4C#N PCXSBVQMMUHDPY-RXFZURLPSA-N 0.000 claims 1
- ACQWIAVWDCJLJK-NRFANRHFSA-N (2S)-2-[4-(3-cyanophenyl)-6-(5-methyl-1H-1,2,4-triazol-3-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C(#N)C=1C=C(C=CC=1)C1=C2CCN(C2=CC(=C1)C1=NN=C(N1)C)C(=O)[C@H]1N(CCC1)C#N ACQWIAVWDCJLJK-NRFANRHFSA-N 0.000 claims 1
- TVHPJDRLSFVKMM-AVAKVYKDSA-N (2S)-2-[4-(3-cyclopropylpyrazolidin-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C1C[C@H](N(C1)C#N)C(=O)N2CCC3=C(C=CC=C32)C4CNNC4C5CC5 TVHPJDRLSFVKMM-AVAKVYKDSA-N 0.000 claims 1
- VGXSHTSUKOOVIG-FQEVSTJZSA-N (2S)-2-[4-(3-methoxyphenyl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound COC=1C=C(C=CC=1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N VGXSHTSUKOOVIG-FQEVSTJZSA-N 0.000 claims 1
- SLJKHYWZWJNXQN-NRFANRHFSA-N (2S)-2-[4-(4-cyanophenyl)-6-(5-methyl-1H-1,2,4-triazol-3-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C(#N)C1=CC=C(C=C1)C1=C2CCN(C2=CC(=C1)C1=NN=C(N1)C)C(=O)[C@H]1N(CCC1)C#N SLJKHYWZWJNXQN-NRFANRHFSA-N 0.000 claims 1
- FVZXOSYEKUHRSU-KRWDZBQOSA-N (2S)-2-[4-(5-methyl-1H-pyrazol-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CC1=C(C=NN1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N FVZXOSYEKUHRSU-KRWDZBQOSA-N 0.000 claims 1
- AIDJSSPSMPDBMV-HNNXBMFYSA-N (2S)-2-[4-[5-(trifluoromethyl)-1H-pyrazol-4-yl]-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound FC(C1=C(C=NN1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N)(F)F AIDJSSPSMPDBMV-HNNXBMFYSA-N 0.000 claims 1
- ZTFYENXJVUNCMA-ZDUSSCGKSA-N (2S)-2-[4-[5-(trifluoromethyl)-1H-pyrazol-4-yl]-2,3-dihydropyrrolo[3,2-c]pyridine-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound FC(C1=C(C=NN1)C1=NC=CC2=C1CCN2C(=O)[C@H]1N(CCC1)C#N)(F)F ZTFYENXJVUNCMA-ZDUSSCGKSA-N 0.000 claims 1
- UMJRIWVVIRJDFL-NRFANRHFSA-N (2S)-2-[5-(1-methylindazol-5-yl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CN1N=CC2=CC(=CC=C12)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N UMJRIWVVIRJDFL-NRFANRHFSA-N 0.000 claims 1
- YOPQXVMPFMTKLY-FQEVSTJZSA-N (2S)-2-[5-(2-cyanophenyl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C(#N)C1=C(C=CC=C1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N YOPQXVMPFMTKLY-FQEVSTJZSA-N 0.000 claims 1
- HKTUPWJHHQLKKU-KRWDZBQOSA-N (2S)-2-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CC1=NOC(=C1C=1C=C2CCN(C2=CC=1)C(=O)[C@H]1N(CCC1)C#N)C HKTUPWJHHQLKKU-KRWDZBQOSA-N 0.000 claims 1
- NAJHZPGWDIYZGC-IBGZPJMESA-N (2S)-2-[5-(3-cyano-2-fluorophenyl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C(#N)C=1C(=C(C=CC=1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N)F NAJHZPGWDIYZGC-IBGZPJMESA-N 0.000 claims 1
- WRFQTTNBJCSRCN-FQEVSTJZSA-N (2S)-2-[5-(3-cyanophenyl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C(#N)C=1C=C(C=CC=1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N WRFQTTNBJCSRCN-FQEVSTJZSA-N 0.000 claims 1
- QFEQKVJBDNLCAH-UHTQNSLKSA-N (2S)-2-[5-(3-methyl-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CC1C2CCC(CC2NN1)C3=CC4=C(CN(C4)C(=O)[C@@H]5CCCN5C#N)C=C3 QFEQKVJBDNLCAH-UHTQNSLKSA-N 0.000 claims 1
- GFCNPYUHBGCNDP-IBGZPJMESA-N (2S)-2-[5-(3-nitrophenyl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound [N+](=O)([O-])C=1C=C(C=CC=1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N GFCNPYUHBGCNDP-IBGZPJMESA-N 0.000 claims 1
- HMBGZKFBFMGLBA-FQEVSTJZSA-N (2S)-2-[5-(4-cyanophenyl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C(#N)C1=CC=C(C=C1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N HMBGZKFBFMGLBA-FQEVSTJZSA-N 0.000 claims 1
- XJORGKDALFSCCA-FQEVSTJZSA-N (2S)-2-[5-(4-methylsulfonylphenyl)-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CS(=O)(=O)C1=CC=C(C=C1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N XJORGKDALFSCCA-FQEVSTJZSA-N 0.000 claims 1
- NMCNSAXVHYTCSP-IBGZPJMESA-N (2S)-2-[5-[3-(trifluoromethoxy)phenyl]-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound FC(OC=1C=C(C=CC=1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N)(F)F NMCNSAXVHYTCSP-IBGZPJMESA-N 0.000 claims 1
- NJKYHSIJIMVBPR-PCKAHOCUSA-N (2S)-2-[5-[3-(trifluoromethyl)pyrazolidin-4-yl]-1,3-dihydroisoindole-2-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C1C[C@H](N(C1)C#N)C(=O)N2CC3=C(C2)C=C(C=C3)C4CNNC4C(F)(F)F NJKYHSIJIMVBPR-PCKAHOCUSA-N 0.000 claims 1
- UWIAIQJNMUKTFT-SIWZUTFBSA-N (2S)-2-[5-[3-(trifluoromethyl)pyrazolidin-4-yl]-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound C1C[C@H](N(C1)C#N)C(=O)N2CCC3=C2C=CC(=C3)C4CNNC4C(F)(F)F UWIAIQJNMUKTFT-SIWZUTFBSA-N 0.000 claims 1
- COCVMGPHJWIQML-FQEVSTJZSA-N (2S)-2-[6-(5-methyl-1H-1,2,4-triazol-3-yl)-4-phenyl-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound CC=1NC(=NN=1)C1=CC(=C2CCN(C2=C1)C(=O)[C@H]1N(CCC1)C#N)C1=CC=CC=C1 COCVMGPHJWIQML-FQEVSTJZSA-N 0.000 claims 1
- XOANBZMRYZSVBZ-INIZCTEOSA-N (2S)-4,4-difluoro-2-[4-(5-methyl-1H-pyrazol-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound FC1(C[C@H](N(C1)C#N)C(=O)N1CCC2=C(C=CC=C12)C=1C=NNC=1C)F XOANBZMRYZSVBZ-INIZCTEOSA-N 0.000 claims 1
- BHILSXATFZMXGG-AWEZNQCLSA-N (2S)-4,4-difluoro-2-[4-[5-(trifluoromethyl)-1H-pyrazol-4-yl]-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound FC1(C[C@H](N(C1)C#N)C(=O)N1CCC2=C(C=CC=C12)C=1C=NNC=1C(F)(F)F)F BHILSXATFZMXGG-AWEZNQCLSA-N 0.000 claims 1
- SAMGWGZMVFDEQB-JTQLQIEISA-N (2S)-N-(4-tert-butyl-1,3-thiazol-2-yl)-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound C(C)(C)(C)C=1N=C(SC=1)N(C(=O)[C@H]1N(CCC1)C#N)C SAMGWGZMVFDEQB-JTQLQIEISA-N 0.000 claims 1
- OZQSHOAYDYFPRI-HNNXBMFYSA-N (2S)-N-(5-benzyl-1,3-thiazol-2-yl)-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound C(C1=CC=CC=C1)C1=CN=C(S1)N(C(=O)[C@H]1N(CCC1)C#N)C OZQSHOAYDYFPRI-HNNXBMFYSA-N 0.000 claims 1
- RLYNKSMCPXKHJQ-AWEZNQCLSA-N (2S)-N-[3-(2-chlorophenyl)-1,2-oxazol-5-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound ClC1=C(C=CC=C1)C1=NOC(=C1)N(C(=O)[C@H]1N(CCC1)C#N)C RLYNKSMCPXKHJQ-AWEZNQCLSA-N 0.000 claims 1
- ITPZQAOZSCHWGH-AWEZNQCLSA-N (2S)-N-[3-(3-chlorophenyl)-1,2-oxazol-5-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound ClC=1C=C(C=CC=1)C1=NOC(=C1)N(C(=O)[C@H]1N(CCC1)C#N)C ITPZQAOZSCHWGH-AWEZNQCLSA-N 0.000 claims 1
- UGRRMXPVIFJDNJ-AWEZNQCLSA-N (2S)-N-[3-(4-chlorophenyl)-1,2-oxazol-5-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound ClC1=CC=C(C=C1)C1=NOC(=C1)N(C(=O)[C@H]1N(CCC1)C#N)C UGRRMXPVIFJDNJ-AWEZNQCLSA-N 0.000 claims 1
- KTBZQJVLCMGVDY-AWEZNQCLSA-N (2S)-N-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound ClC1=C(C=CC=C1)C=1N=C(SC=1)N(C(=O)[C@H]1N(CCC1)C#N)C KTBZQJVLCMGVDY-AWEZNQCLSA-N 0.000 claims 1
- SQNJTBNFEHPSFE-INIZCTEOSA-N (2S)-N-[4-(3-acetamidophenyl)-1,3-thiazol-2-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound C(C)(=O)NC=1C=C(C=CC=1)C=1N=C(SC=1)N(C(=O)[C@H]1N(CCC1)C#N)C SQNJTBNFEHPSFE-INIZCTEOSA-N 0.000 claims 1
- HLYWOXLKZGUNLZ-AWEZNQCLSA-N (2S)-N-[4-(3-chloro-4-fluorophenyl)-1,3-thiazol-2-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound ClC=1C=C(C=CC=1F)C=1N=C(SC=1)N(C(=O)[C@H]1N(CCC1)C#N)C HLYWOXLKZGUNLZ-AWEZNQCLSA-N 0.000 claims 1
- MPFJAXKSYDXRGF-AWEZNQCLSA-N (2S)-N-[4-(3-chlorophenyl)-1,3-thiazol-2-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound ClC=1C=C(C=CC=1)C=1N=C(SC=1)N(C(=O)[C@H]1N(CCC1)C#N)C MPFJAXKSYDXRGF-AWEZNQCLSA-N 0.000 claims 1
- NYHSLNVRVJOYFH-AWEZNQCLSA-N (2S)-N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound ClC1=CC=C(C=C1)C=1N=C(SC=1)N(C(=O)[C@H]1N(CCC1)C#N)C NYHSLNVRVJOYFH-AWEZNQCLSA-N 0.000 claims 1
- NJKJVEDERGWOOB-KRWDZBQOSA-N (2S)-N-[4-[3-[acetyl(methyl)amino]phenyl]-1,3-thiazol-2-yl]-1-cyano-N-methylpyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=CC(=CC=C1)N(C(C)=O)C)C NJKJVEDERGWOOB-KRWDZBQOSA-N 0.000 claims 1
- RQELPKFGBFTZSL-QUCCMNQESA-N (2S,4S)-1-cyano-N-methyl-4-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound C(#N)N1[C@@H](C[C@H](C1)C1=CC=CC=C1)C(=O)N(C=1SC=C(N=1)C1=CC=CC=C1)C RQELPKFGBFTZSL-QUCCMNQESA-N 0.000 claims 1
- BIKCGHPVEKXRAG-SJCJKPOMSA-N (2S,4S)-4-fluoro-2-[4-(5-methyl-1H-pyrazol-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound F[C@H]1C[C@H](N(C1)C#N)C(=O)N1CCC2=C(C=CC=C12)C=1C=NNC=1C BIKCGHPVEKXRAG-SJCJKPOMSA-N 0.000 claims 1
- AHCBJXSHVXHGHF-BONVTDFDSA-N (2S,4S)-4-fluoro-2-[4-[5-(trifluoromethyl)-1H-pyrazol-4-yl]-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carbonitrile Chemical compound F[C@H]1C[C@H](N(C1)C#N)C(=O)N1CCC2=C(C=CC=C12)C=1C=NNC=1C(F)(F)F AHCBJXSHVXHGHF-BONVTDFDSA-N 0.000 claims 1
- DJQHWGVEXLMBAZ-JXFKEZNVSA-N (2S,4S)-4-methoxy-2-(4-phenyl-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carbonitrile Chemical compound CO[C@H]1C[C@H](N(C1)C#N)C(=O)N1CCC2=C(C=CC=C12)C1=CC=CC=C1 DJQHWGVEXLMBAZ-JXFKEZNVSA-N 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- HMDPLQQUMZHZRG-IBGZPJMESA-N 1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-4-(3,4-dichlorophenyl)-N-methyl-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)c1cc2N(CCc2c(c1)-c1ccc(Cl)c(Cl)c1)C(=O)[C@@H]1CCCN1C#N HMDPLQQUMZHZRG-IBGZPJMESA-N 0.000 claims 1
- YBGZJESLGRCDEE-NRFANRHFSA-N 1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-4-(3-ethylphenyl)-N-methyl-2,3-dihydroindole-6-carboxamide Chemical compound CCC1=CC=CC(=C1)C1=CC(=CC2=C1CCN2C(=O)[C@@H]1CCCN1C#N)C(=O)NC YBGZJESLGRCDEE-NRFANRHFSA-N 0.000 claims 1
- WFXCOIDBGACSFK-FQEVSTJZSA-N 1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-ethyl-4-phenyl-2,3-dihydroindole-6-carboxamide Chemical compound CCNC(=O)C1=CC2=C(CCN2C(=O)[C@@H]2CCCN2C#N)C(=C1)C1=CC=CC=C1 WFXCOIDBGACSFK-FQEVSTJZSA-N 0.000 claims 1
- KEWYUVLIPGUNSG-IBGZPJMESA-N 1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)C1=CC2=C(CCN2C(=O)[C@@H]2CCCN2C#N)C(=C1)C1=CNC2=C1C=CC=N2 KEWYUVLIPGUNSG-IBGZPJMESA-N 0.000 claims 1
- LHZGPCBUTBOMOE-IBGZPJMESA-N 1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-4-[4-(trifluoromethyl)phenyl]-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)C1=CC(=C2CCN(C(=O)[C@@H]3CCCN3C#N)C2=C1)C1=CC=C(C=C1)C(F)(F)F LHZGPCBUTBOMOE-IBGZPJMESA-N 0.000 claims 1
- FDMMUQYTSILOPR-QFIPXVFZSA-N 1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-4-quinolin-6-yl-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)C1=CC2=C(CCN2C(=O)[C@@H]2CCCN2C#N)C(=C1)C1=CC2=C(C=C1)N=CC=C2 FDMMUQYTSILOPR-QFIPXVFZSA-N 0.000 claims 1
- 208000009270 3-hydroxyacyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- FTDLODJAIMNALU-SFHVURJKSA-N 4-(1,3-benzodioxol-5-yl)-1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)c1cc2N(CCc2c(c1)-c1ccc2OCOc2c1)C(=O)[C@@H]1CCCN1C#N FTDLODJAIMNALU-SFHVURJKSA-N 0.000 claims 1
- WHFKIEYBBULDCZ-IBGZPJMESA-N 4-(2-chlorophenyl)-1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)c1cc2N(CCc2c(c1)-c1ccccc1Cl)C(=O)[C@@H]1CCCN1C#N WHFKIEYBBULDCZ-IBGZPJMESA-N 0.000 claims 1
- CUARZSQLWSSUBD-FQEVSTJZSA-N 4-(3-cyanophenyl)-1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)c1cc2N(CCc2c(c1)-c1cccc(c1)C#N)C(=O)[C@@H]1CCCN1C#N CUARZSQLWSSUBD-FQEVSTJZSA-N 0.000 claims 1
- OMYYPBQIHHRCPF-IBGZPJMESA-N 4-(4-chlorophenyl)-1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)c1cc2N(CCc2c(c1)-c1ccc(Cl)cc1)C(=O)[C@@H]1CCCN1C#N OMYYPBQIHHRCPF-IBGZPJMESA-N 0.000 claims 1
- SQEIQQQQYKFXCH-FQEVSTJZSA-N 4-(4-cyanophenyl)-1-[(2S)-1-cyanopyrrolidine-2-carbonyl]-N-methyl-2,3-dihydroindole-6-carboxamide Chemical compound CNC(=O)c1cc2N(CCc2c(c1)-c1ccc(cc1)C#N)C(=O)[C@@H]1CCCN1C#N SQEIQQQQYKFXCH-FQEVSTJZSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000005943 Barth syndrome Diseases 0.000 claims 1
- WLUCIYYGHLKLSV-FQEVSTJZSA-N C(#N)C1=C(C=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound C(#N)C1=C(C=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N WLUCIYYGHLKLSV-FQEVSTJZSA-N 0.000 claims 1
- LURHVDXFRRUNIS-FQEVSTJZSA-N C(#N)C1=CC=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound C(#N)C1=CC=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N LURHVDXFRRUNIS-FQEVSTJZSA-N 0.000 claims 1
- WNYLPSCEQVXVEU-FQEVSTJZSA-N C(#N)C=1C=C(C=CC=1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound C(#N)C=1C=C(C=CC=1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N WNYLPSCEQVXVEU-FQEVSTJZSA-N 0.000 claims 1
- IORAJTZSNAZPSA-LBPRGKRZSA-N C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=NC(=CC=C1)C(F)(F)F)C Chemical compound C(#N)N1[C@@H](CCC1)C(=O)N(C=1SC=C(N=1)C1=NC(=CC=C1)C(F)(F)F)C IORAJTZSNAZPSA-LBPRGKRZSA-N 0.000 claims 1
- RGFNLDIHPNPDQW-HNNXBMFYSA-N C(C)(C)OC1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound C(C)(C)OC1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N RGFNLDIHPNPDQW-HNNXBMFYSA-N 0.000 claims 1
- PTEPIQYGZOAPCJ-IBGZPJMESA-N C1(=CC=CC=C1)C=1C=C2CCN(C2=CC=1)C(=O)[C@H]1N(CCC1)C#N Chemical compound C1(=CC=CC=C1)C=1C=C2CCN(C2=CC=1)C(=O)[C@H]1N(CCC1)C#N PTEPIQYGZOAPCJ-IBGZPJMESA-N 0.000 claims 1
- AEWPXKRBWMHBRQ-IBGZPJMESA-N C1(=CC=CC=C1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N Chemical compound C1(=CC=CC=C1)C=1C=C2CN(CC2=CC=1)C(=O)[C@H]1N(CCC1)C#N AEWPXKRBWMHBRQ-IBGZPJMESA-N 0.000 claims 1
- AHXHFWKYIYXQMV-INIZCTEOSA-N C1(CC1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound C1(CC1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N AHXHFWKYIYXQMV-INIZCTEOSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- GPNAJIZRASNSIG-FQEVSTJZSA-N CC1=C(C(=CC=C1)C)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound CC1=C(C(=CC=C1)C)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N GPNAJIZRASNSIG-FQEVSTJZSA-N 0.000 claims 1
- DTPPEGSKBHKTOF-KRWDZBQOSA-N CC1=C(C=NO1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound CC1=C(C=NO1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N DTPPEGSKBHKTOF-KRWDZBQOSA-N 0.000 claims 1
- VQXZQBLOCQIOOC-KRWDZBQOSA-N CC1=C(C=NO1)C=1C=C2CCN(C2=CC=1)C(=O)[C@H]1N(CCC1)C#N Chemical compound CC1=C(C=NO1)C=1C=C2CCN(C2=CC=1)C(=O)[C@H]1N(CCC1)C#N VQXZQBLOCQIOOC-KRWDZBQOSA-N 0.000 claims 1
- QXXVNRVLJDODMU-KRWDZBQOSA-N CNC1=NC=CC(=N1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound CNC1=NC=CC(=N1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N QXXVNRVLJDODMU-KRWDZBQOSA-N 0.000 claims 1
- LMVCADKTOPZYBN-IBGZPJMESA-N COC1=C(C=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound COC1=C(C=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N LMVCADKTOPZYBN-IBGZPJMESA-N 0.000 claims 1
- NXYQNEYXTVQPQF-FQEVSTJZSA-N COC1=CC=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound COC1=CC=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N NXYQNEYXTVQPQF-FQEVSTJZSA-N 0.000 claims 1
- DJQHWGVEXLMBAZ-UZLBHIALSA-N CO[C@@H]1C[C@H](N(C1)C#N)C(=O)N1CCC2=C(C=CC=C12)C1=CC=CC=C1 Chemical compound CO[C@@H]1C[C@H](N(C1)C#N)C(=O)N1CCC2=C(C=CC=C12)C1=CC=CC=C1 DJQHWGVEXLMBAZ-UZLBHIALSA-N 0.000 claims 1
- XTBVWWRXYVWTQH-FQEVSTJZSA-N C[Si](C)(C)C#CC1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C Chemical compound C[Si](C)(C)C#CC1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C XTBVWWRXYVWTQH-FQEVSTJZSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 claims 1
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims 1
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 claims 1
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- VMYMUPNFTDKDMR-IBGZPJMESA-N ClC=1C=C(C=CC=1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound ClC=1C=C(C=CC=1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N VMYMUPNFTDKDMR-IBGZPJMESA-N 0.000 claims 1
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000021075 Creatine deficiency syndrome Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 102000015782 Electron Transport Complex III Human genes 0.000 claims 1
- 108010024882 Electron Transport Complex III Proteins 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims 1
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims 1
- 101710150008 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims 1
- 206010072928 Mucolipidosis type II Diseases 0.000 claims 1
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- HFYHHCUUAZHVOR-KRWDZBQOSA-N N1=C2C(=NC=C1)NC=C2C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound N1=C2C(=NC=C1)NC=C2C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N HFYHHCUUAZHVOR-KRWDZBQOSA-N 0.000 claims 1
- KHDWCTFCLZXTEQ-SFHVURJKSA-N N1=CC(=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound N1=CC(=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N KHDWCTFCLZXTEQ-SFHVURJKSA-N 0.000 claims 1
- SOGGLSWYHHABAC-KRWDZBQOSA-N N1=CN=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound N1=CN=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N SOGGLSWYHHABAC-KRWDZBQOSA-N 0.000 claims 1
- FJHVMDWNTLUVSA-KRWDZBQOSA-N N1=NC=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound N1=NC=C(C=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N FJHVMDWNTLUVSA-KRWDZBQOSA-N 0.000 claims 1
- YOGAXMPPMMXAEY-INIZCTEOSA-N NC1=CN=CC(=N1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound NC1=CN=CC(=N1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N YOGAXMPPMMXAEY-INIZCTEOSA-N 0.000 claims 1
- PGWVBDMLLJFVDO-INIZCTEOSA-N NC1=NC=C(C=N1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound NC1=NC=C(C=N1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N PGWVBDMLLJFVDO-INIZCTEOSA-N 0.000 claims 1
- IREHCLMOMHIEHD-SFHVURJKSA-N O(C1=CC=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N Chemical compound O(C1=CC=CC=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C#N IREHCLMOMHIEHD-SFHVURJKSA-N 0.000 claims 1
- CXGNWVHMUQBCPU-IBGZPJMESA-N O(C1=CC=CC=C1)C=1C=C2CCN(C2=CC=1)C(=O)[C@H]1N(CCC1)C#N Chemical compound O(C1=CC=CC=C1)C=1C=C2CCN(C2=CC=1)C(=O)[C@H]1N(CCC1)C#N CXGNWVHMUQBCPU-IBGZPJMESA-N 0.000 claims 1
- 102100035196 POLG alternative reading frame Human genes 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 208000013234 Pearson syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 claims 1
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- APNYYKPFLAHMIB-HNNXBMFYSA-N methyl 4-bromo-1-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]-2,3-dihydroindole-6-carboxylate Chemical compound COC(=O)C1=CC(Br)=C2CCN(C(=O)[C@@H]3CCCN3C(=O)OC(C)(C)C)C2=C1 APNYYKPFLAHMIB-HNNXBMFYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims 1
- 208000020468 mucolipidosis III alpha/beta Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 claims 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- MBSCHPZZVVPDMW-HNNXBMFYSA-N tert-butyl (2S)-2-(4-bromo-2,3-dihydroindole-1-carbonyl)pyrrolidine-1-carboxylate Chemical compound BrC1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C MBSCHPZZVVPDMW-HNNXBMFYSA-N 0.000 claims 1
- GFWQTQCAFKEBJY-QFIPXVFZSA-N tert-butyl (2S)-2-(5-phenyl-3,4-dihydro-1H-isoquinoline-2-carbonyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)N1CCC2=C(C1)C=CC=C2C1=CC=CC=C1 GFWQTQCAFKEBJY-QFIPXVFZSA-N 0.000 claims 1
- FVXNFTFVFLVUAU-IBGZPJMESA-N tert-butyl (2S)-2-[4-(2-aminopyridin-4-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC1=NC=CC(=C1)C1=C2CCN(C2=CC=C1)C(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C FVXNFTFVFLVUAU-IBGZPJMESA-N 0.000 claims 1
- WJDNWLZOVHJGIK-NRFANRHFSA-N tert-butyl (2S)-2-[4-phenyl-6-(1H-1,2,4-triazol-5-yl)-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)N1CCC2=C(C=C(C=C12)C1=NN=CN1)C1=CC=CC=C1 WJDNWLZOVHJGIK-NRFANRHFSA-N 0.000 claims 1
- ZBKMMWZJRWVUKF-QFIPXVFZSA-N tert-butyl (2S)-2-[6-(1H-imidazol-2-yl)-4-phenyl-2,3-dihydroindole-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)N1CCC2=C(C=C(C=C12)C1=NC=CN1)C1=CC=CC=C1 ZBKMMWZJRWVUKF-QFIPXVFZSA-N 0.000 claims 1
- IDGCQIKYYGMWLZ-KRWDZBQOSA-N tert-butyl (2S)-2-[[4-(3-chlorophenyl)-1,3-thiazol-2-yl]-ethylcarbamoyl]pyrrolidine-1-carboxylate Chemical compound CCN(C(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C)C1=NC(=CS1)C1=CC(Cl)=CC=C1 IDGCQIKYYGMWLZ-KRWDZBQOSA-N 0.000 claims 1
- SFITVTVUGOFBQN-SFHVURJKSA-N tert-butyl (2S)-2-[[4-(4-acetamidophenyl)-1,3-thiazol-2-yl]-methylcarbamoyl]pyrrolidine-1-carboxylate Chemical compound CN(C(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C)C1=NC(=CS1)C1=CC=C(NC(C)=O)C=C1 SFITVTVUGOFBQN-SFHVURJKSA-N 0.000 claims 1
- AMSVWAAHYCTIPV-AWEZNQCLSA-N tert-butyl (2S)-2-[[5-(3-bromophenyl)-1,2-oxazol-3-yl]carbamoyl]pyrrolidine-1-carboxylate Chemical compound BrC=1C=C(C=CC=1)C1=CC(=NO1)NC(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C AMSVWAAHYCTIPV-AWEZNQCLSA-N 0.000 claims 1
- FPDGCJCXKOPYMM-HNNXBMFYSA-N tert-butyl (2S)-2-[[5-(3-chlorophenyl)-1,2-oxazol-3-yl]-methylcarbamoyl]pyrrolidine-1-carboxylate Chemical compound CN(C(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C)C1=NOC(=C1)C1=CC(Cl)=CC=C1 FPDGCJCXKOPYMM-HNNXBMFYSA-N 0.000 claims 1
- CRFZMUGEOKSLSK-INIZCTEOSA-N tert-butyl (2S)-2-[[5-(3-methoxyphenyl)-1,2-oxazol-3-yl]-methylcarbamoyl]pyrrolidine-1-carboxylate Chemical compound COC=1C=C(C=CC=1)C1=CC(=NO1)N(C(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C)C CRFZMUGEOKSLSK-INIZCTEOSA-N 0.000 claims 1
- KNMIHEMZRYEGMW-RDJZCZTQSA-N tert-butyl (2S,4S)-4-methoxy-2-[methyl-(4-phenyl-1,3-thiazol-2-yl)carbamoyl]pyrrolidine-1-carboxylate Chemical compound CO[C@H]1C[C@H](N(C1)C(=O)OC(C)(C)C)C(N(C=1SC=C(N=1)C1=CC=CC=C1)C)=O KNMIHEMZRYEGMW-RDJZCZTQSA-N 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512270.8A GB201512270D0 (en) | 2015-07-14 | 2015-07-14 | Novel Compounds |
| GB1512270.8 | 2015-07-14 | ||
| GB1604642.7 | 2016-03-18 | ||
| GBGB1604642.7A GB201604642D0 (en) | 2016-03-18 | 2016-03-18 | Novel compounds |
| PCT/GB2016/052130 WO2017009650A1 (en) | 2015-07-14 | 2016-07-14 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524367A JP2018524367A (ja) | 2018-08-30 |
| JP2018524367A5 true JP2018524367A5 (enExample) | 2019-08-22 |
| JP6802251B2 JP6802251B2 (ja) | 2020-12-16 |
Family
ID=56618186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501285A Active JP6802251B2 (ja) | 2015-07-14 | 2016-07-14 | 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10669234B2 (enExample) |
| EP (2) | EP3322702B1 (enExample) |
| JP (1) | JP6802251B2 (enExample) |
| CN (1) | CN107849013B (enExample) |
| ES (1) | ES2773046T3 (enExample) |
| WO (1) | WO2017009650A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| MY188957A (en) | 2015-03-30 | 2022-01-14 | Mission Therapeutics Ltd | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| US10669234B2 (en) | 2015-07-14 | 2020-06-02 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) * | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| JP6959332B2 (ja) | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) * | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019213570A1 (en) * | 2018-05-04 | 2019-11-07 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CN112384500B (zh) * | 2018-07-12 | 2024-05-14 | 贝达药业股份有限公司 | 免疫调节剂及其组合物和制备方法 |
| JP7434285B2 (ja) | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
| PL3860989T3 (pl) | 2018-10-05 | 2023-07-10 | Forma Therapeutics, Inc. | Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30) |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| JP7734917B2 (ja) | 2019-01-28 | 2025-09-08 | ミトコンドリア エモーション， インク． | トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 |
| JP7473565B2 (ja) | 2019-01-28 | 2024-04-23 | ミトコンドリア エモーション， インク． | マイトフュージン活性化物質及びその使用方法 |
| CN109776377B (zh) * | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
| US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251971A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| US20230093080A1 (en) * | 2019-07-15 | 2023-03-23 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2021011631A1 (en) * | 2019-07-15 | 2021-01-21 | Kymera Therapeutics, Inc. | Fused-glutarimide crbn ligands and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| KR20220110744A (ko) | 2019-11-06 | 2022-08-09 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| EP4072591A4 (en) | 2019-12-10 | 2024-06-05 | Kymera Therapeutics, Inc. | IRAQ DEGRADER AND USES THEREOF |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
| IL296451B2 (en) | 2020-03-19 | 2026-05-01 | Kymera Therapeutics Inc | MDM2 joints and their uses |
| BR112022020058A2 (pt) | 2020-04-08 | 2022-11-22 | Mission Therapeutics Ltd | N-cianopirrolidinas com atividade como inibidores de usp30 |
| BR112022020644A2 (pt) | 2020-05-28 | 2022-12-06 | Mission Therapeutics Ltd | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| JP7796047B2 (ja) | 2020-06-04 | 2026-01-08 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン |
| DK4161929T3 (da) | 2020-06-08 | 2025-08-18 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose |
| CN115916776A (zh) * | 2020-06-09 | 2023-04-04 | 艾尼莫生物科技公司 | 胶原蛋白1翻译抑制剂及其使用方法 |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2022147465A1 (en) | 2020-12-30 | 2022-07-07 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| US20240335427A1 (en) * | 2021-07-26 | 2024-10-10 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2) |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| CN114478577A (zh) * | 2021-12-08 | 2022-05-13 | 河北合佳创新医药科技有限公司 | 一种n-甲酰基头孢噻肟的制备方法 |
| AU2023211607A1 (en) * | 2022-01-28 | 2024-08-22 | Opna Bio SA | Compounds and methods for yap/tead modulation and indications therefor |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| CN119528901A (zh) * | 2024-11-05 | 2025-02-28 | 上海市同济医院 | 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001077073A1 (en) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| AR071480A1 (es) | 2008-04-18 | 2010-06-23 | Glaxo Group Ltd | Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd ) |
| WO2012040527A2 (en) | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| JP2015508414A (ja) * | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| US10669234B2 (en) | 2015-07-14 | 2020-06-02 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
-
2016
- 2016-07-14 US US15/738,900 patent/US10669234B2/en active Active
- 2016-07-14 WO PCT/GB2016/052130 patent/WO2017009650A1/en not_active Ceased
- 2016-07-14 EP EP16750199.8A patent/EP3322702B1/en active Active
- 2016-07-14 ES ES16750199T patent/ES2773046T3/es active Active
- 2016-07-14 CN CN201680040161.0A patent/CN107849013B/zh active Active
- 2016-07-14 JP JP2018501285A patent/JP6802251B2/ja active Active
- 2016-07-14 EP EP19209239.3A patent/EP3800186B1/en active Active
-
2020
- 2020-04-08 US US16/843,339 patent/US11319287B2/en active Active